# Glaxosmithkline Pharmaceuticals share price today (Glaxosmithkline Pharmaceuticals Ltd, NSE: GLAXO)

> Glaxosmithkline Pharmaceuticals share price today: ₹2,575.10 at the NSE close on 3 November 2026, down 1.7% in a year. Glaxosmithkline Pharmaceuticals (NSE: GLAXO) is worth ₹43,629 crore, trades at a P/E of 41.4 and has closed between ₹2,121.50 and ₹3,106.40 over the past 52 weeks. > Glaxosmithkline Pharmaceuticals Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 8% of past readings. GLAXO · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹2,575.10 (−1.7% in a year)
- P/E: 41.4× (lower than 92% of the last 11 years)
- Revenue (Jun 2026): ₹938 Cr (+16.5% on a year ago)
- Profit (Jun 2026): ₹237 Cr (+15.6% on a year ago)
- Operating margin: 31.0% (flat on a year ago)
- ROCE: 61%, FY26
- ROIC: 37.9%, against a 12.0% cost of capital: +25.9 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Glaxosmithkline Pharmaceuticals share price today? Glaxosmithkline Pharmaceuticals Ltd's share price was ₹2,575.10 at the close on 3 November 2026. It has been rising for 11 weeks. That is 0.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,122 and ₹3,106, and at that close it sat 46% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +59% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Glaxosmithkline Pharmaceuticals this quarter? One change stood out: profit up on a year earlier for 10 quarters in a row. 1. Profit up on a year earlier for 10 quarters in a row In the June 2026 quarter profit was ₹237 crore, +15.6% on a year earlier. Why: Profit rose because the company got better prices and sold more of the higher-value products, which widened the gap between sales and direct product costs. Next results: check whether the heavy spending on launches in the first quarter calms down and the profit margin stays near last year's level. From the earnings call on 3 Aug 2026. ## What are Glaxosmithkline Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Glaxosmithkline Pharmaceuticals reported revenue of ₹938 crore, up 16.5% from ₹805 crore a year earlier, and a profit of ₹237 crore, up 15.6% from ₹205 crore. ### Glaxosmithkline Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹938 crore | ₹805 crore | +16.5% |
| Profit | ₹237 crore | ₹205 crore | +15.6% |
| Earnings per share | ₹14.00 | ₹12.10 | +15.7% |
| Operating margin | 31.0% | 31.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Glaxosmithkline Pharmaceuticals' management discussed these results on a call held on 3 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Glaxosmithkline Pharmaceuticals share price history? Glaxosmithkline Pharmaceuticals closed at ₹2,575.10 on 3 November 2026, down 1.7% from ₹2,618.60 a year earlier (31 October 2025) and up 56.8% over five years. Its highest weekly close since March 2016 was ₹3,439.60 on 27 June 2025. ### Glaxosmithkline Pharmaceuticals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹2,404.70 | +7.1% |
| 1 month ago · 1 Oct 2026 | ₹2,771.10 | −7.1% |
| 6 months ago · 30 Apr 2026 | ₹2,336.40 | +10.2% |
| 1 year ago · 31 Oct 2025 | ₹2,618.60 | −1.7% |
| 3 years ago · 3 Nov 2023 | ₹1,405.15 | +83.3% |
| 5 years ago · 4 Nov 2021 | ₹1,642.30 | +56.8% |
| 10 years ago · 4 Nov 2016 | ₹1,400.38 | +83.9% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹1,622.43 | +58.7% |
| Highest weekly close since March 2016 · 27 Jun 2025 | ₹3,439.60 | −25.1% |
| Lowest weekly close since March 2016 · 28 Mar 2018 | ₹1,043.88 | +146.7% |
| 52-week high (weekly close) · 28 Aug 2026 | ₹3,106.40 | −17.1% |
| 52-week low (weekly close) · 12 Jun 2026 | ₹2,121.50 | +21.4% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Glaxosmithkline Pharmaceuticals? 3 Nov 2026: Glaxosmithkline Pharmaceuticals closed at ₹2,575.10, up 7.1% on the week and down 7.1% on the month. 3 Aug 2026: Glaxosmithkline Pharmaceuticals held its results call for April to June 2026. Management guided: Established GenMed and vaccine businesses planned at 8-10% growth over the 4-5-year 2X horizon, with innovation driving the 13% growth ambition. ### Earlier

- Results for April to June 2026: Revenue up 16.5% and profit up 15.6% on a year earlier. - 29 May 2026: ex-date for a dividend of ₹57 a share. ## What dividend does Glaxosmithkline Pharmaceuticals pay? Glaxosmithkline Pharmaceuticals paid ₹57 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 2.21% at the ₹2,575.10 close on 3 November 2026. The last was a dividend of ₹57 a share, ex-date 29 May 2026. ### Glaxosmithkline Pharmaceuticals dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 29 May 2026 | ₹57 | Dividend | same day |
| 30 May 2025 | ₹42 | Dividend | same day |
| 7 Nov 2024 | ₹12 | Interim | same day |
| 31 May 2024 | ₹32 | Dividend | same day |
| 30 Jun 2023 | ₹32 | Dividend | same day |
| 7 Jul 2022 | ₹90 | Dividend + Special | 8 Jul 2022 |
| 19 Jul 2021 | ₹30 | Dividend | 20 Jul 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Glaxosmithkline Pharmaceuticals Ltd paid out 93% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Glaxosmithkline Pharmaceuticals management say on the latest results call? On the call for April to June 2026, held on 3 August 2026, Glaxosmithkline Pharmaceuticals' management guided: Established GenMed and vaccine businesses planned at 8-10% growth over the 4-5-year 2X horizon, with innovation driving the 13% growth ambition. > “It is safe to say that the worst is behind us.”
> Bhushan Akshikar, on the call for April to June 2026

### What management guided

- Q2 acute-season performance expected to be in line with expectations based on June-July trends. - Opex and SG&A ratios expected to moderate toward historical levels in following quarters after Q1 concentration. - Nucala new-patient momentum to be sustained through the next 2 quarters. - Blenrep launch in the next 2-3 months, most probably Q2 or October to December 2026. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/362/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 3 August 2026.)

## What could change the Glaxosmithkline Pharmaceuticals story? What are the risks? Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units. ### Each change stops working if

- : Adult vaccine adoption in institutional and public accounts decelerates or pricing realizations face mandatory discounting. - : Field force cost inflation outpaces revenue productivity gains or third-party CMO disruptions recur. ### The main risks

- : Trelegy Ellipta faces 10-12 generic competitor versions in the Indian market post-patent expiration. ⚠ estimate
- : Imported drug substance and formulation purchases face cost pressures from Indian Rupee depreciation. ⚠ estimate

(Our read after the latest results, written 22 August 2026.)

## What to watch in Glaxosmithkline Pharmaceuticals' next results? When Glaxosmithkline Pharmaceuticals reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 acute-season demand and vaccine availability - check whether July-September trends track the stated in-line expectation and phasing correction. - What to check (from the call)
- Q2 acute-season demand and vaccine availability - check whether July-September trends track the stated in-line expectation and phasing correction. - Q1 launch-spend normalization - check whether SG&A moderates and operating margin remain around last year's level. - Blenrep launch - check approval-to-patient conversion through the trained oncology and hematology team. - Bepirovirsen roadmap - check for patient-funnel, treatment-duration, and launch-timing detail in the next update. ## Which stock lists is Glaxosmithkline Pharmaceuticals on? Glaxosmithkline Pharmaceuticals is on 3 of our India lists: Dividend stocks, Small & mid cap stocks and Pharma stocks. - [Dividend stocks Regular dividend yield (%): 2.25](https://www.sectoralpha.in/dividend-stocks-india)
- [Small & mid cap stocks Size rank in India: 215](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 42883.497173555705](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Glaxosmithkline Pharmaceuticals profitable? Glaxosmithkline Pharmaceuticals Ltd earned ₹237 Cr of net profit in the Jun 2026 quarter, +15.6% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹1,036 Cr. Over 10 years profit has grown 10.7% a year on average. That is 25.3% of the quarter's revenue. The same quarter a year earlier earned ₹205 Cr. For the full year, FY26 profit was ₹1,036 Cr (+11.6% on the year before). Why profit moved: revenue changed +16.5% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +13.0% and revenue +6.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported. FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much revenue does Glaxosmithkline Pharmaceuticals make, and is it growing? Glaxosmithkline Pharmaceuticals Ltd reported ₹938 Cr of revenue in the Jun 2026 quarter, +16.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown 3.0% a year on average. The last full year, FY26, came in at ₹3,822 Cr. Why this happened. Under the Generic-to-Specialty Value Migration framework, Glaxo is pivoting away from commoditized acute formulations toward IP-protected specialty therapies. In Q1 FY27, specialty assets contributed 7.5% of total sales compared to 4.0% in the prior year period, adding approximately 4 percentage points to headline revenue growth. Key contributors include Shingrix, Nucala, Trelegy, and oncology therapies Zejula and Jemperli. The shift enhances gross margins by 150-190 bps and insulates the revenue base from domestic price controls. The last four reported quarters add to ₹3,954 Cr. FY26 revenue was ₹3,822 Cr, +1.9% on the year before. Recent pace: the last four quarters grew +6.3% on average, against 3.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.8%, against +6.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +12.4%, against +29.2% a year (rolling over). FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported. FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Glaxosmithkline Pharmaceuticals keep? Glaxosmithkline Pharmaceuticals Ltd's operating margin was 31.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 14.0% and 34.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.3 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. FY26-Q4. revenue ₹995 Cr and profit ₹278 Cr as reported. FY27-Q1. revenue ₹938 Cr and profit ₹237 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## Is Glaxosmithkline Pharmaceuticals' profit turning into cash? Over the last 3 years, 109% of Glaxosmithkline Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹903 Cr of operating cash against ₹1,036 Cr of profit. After ₹82.0 Cr of spending on assets, ₹821 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 109% of profit came in as cash: the cash cycle got 54 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Glaxosmithkline Pharmaceuticals' cash go? Glaxosmithkline Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −4 days in FY26, down from 50 days in FY21. It spent ₹167 Cr on assets over the last 3 years. Customers take 26 days to pay, and stock sits for 124 days on average. At FY26 sales of ₹3,822 Cr, each day of that cycle ties up about ₹10.5 Cr, so roughly −₹42.0 Cr is tied up in the business at any time. FY26: customers took 26 days to pay and stock sat for 124 days, about 4.1 months of sales sitting as stock, for a full cycle of −4 days, shorter than FY21's 50. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 124 days. Customers pay about 26 days after that. Suppliers are paid at 154 days. Together that makes the −4-day cycle. Spending on assets: ₹167 Cr over the last 3 years, against ₹203 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹33.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Glaxosmithkline Pharmaceuticals' P/E ratio, and how does it compare with its own history? Glaxosmithkline Pharmaceuticals Ltd's P/E is 41.4×, near the low end of its own history: it has been lower only 8% of the time. Its usual P/E (the middle reading) is 57.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹63.05. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +11.7% while the price moved −1.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +9.4% a year; about +17.4% a year came from earnings growth and about −8.0 percentage points from the multiple (the market paying less); over 10 years the price moved +6.3% a year; about +10.9% a year came from earnings growth and about −4.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Glaxosmithkline Pharmaceuticals share price assume? Worked out from its price on 26 August 2026, Glaxosmithkline Pharmaceuticals Ltd's share price assumed profit growth of about 24.4% a year. Over the past 10 years its profit actually grew 10.7% a year. Today its P/E is 41.4×, lower than 92% of its own last 11 years. This is a one-day reading, taken on 26 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Glaxosmithkline Pharmaceuticals business getting better or worse? Glaxosmithkline Pharmaceuticals Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +57.1% at its peak to +12.4% now), while ROCE is still 61.2%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## What is the Glaxosmithkline Pharmaceuticals story, and has it been checked? Glaxosmithkline Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 22 August 2026. Our read, 22 August 2026. From the numbers. The deterministic cycle engine stamps…

From the price. Price stage 2, week 11, below its 200-day line, relative strength falling. From the research. Where they disagree. The second-order reconciliation confirms…

What is proven. What is not proven yet. Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units. What would change our mind. Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units. The test written in advance. Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units. Measured by: the thesis as written as stated by the next result. The test written in advance. Peak Operating Margin Mean-Reversion Risk. Measured by: Peak Operating Margin Mean-Reversion Risk Quarterly operating profit margin declining below 30% or gross margin contracting by more than 100 bps YoY. by the next result. The test written in advance. National List of Essential Medicines Price Control Exposure. Measured by: National List of Essential Medicines Price Control Exposure NPPA notifications adding key General Medicines formulations to revised NLEM schedules. by the next result. What the company does. Innovation portfolio spanning Shingrix, Nucala, Trelegy, and oncology expanded from 2% to 7.5% of revenue, lifting gross margins by 150 bps and full-year operating margins to 34%. Core General Medicines portfolio provides cash generation with 1.09x three-year cash conversion and negative working capital of -4 days CCC, funding a 93% dividend payout. What the surface reading misses. The surface reading is: OCF-to-PAT of 1.09x over 3 years and 0.87x in FY26 confirms accounting profits convert into cash. The research reads it further: Cash flow is supported by negative working capital (-4 days CCC) where trade payables (154 days) fund receivables (26 days) and inventory (124 days). Capex is minimal at ₹82 Cr in FY26, generating ₹821 Cr FCF to fund a 93% dividend payout. What the surface reading misses. Sources: our stock research file (22 August 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Glaxosmithkline Pharmaceuticals management deliver what it promised? What Glaxosmithkline Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Vaccine Supply Resolution Slipped · 3 August 2026. In May 2026, management explicitly stated that there were no supply constraints in the new financial year's Q1. In Aug 2026, management acknowledged that availability and phasing issues remained for a couple of vaccines and would only be corrected in Q2, extending the expected resolution without explaining the change; this warrants questions about supply continuity and near-term sales timing. Bepirovirsen Commercialization Timeline Extended · 3 August 2026. Both Feb 2026 and May 2026 indicated that Bepirovirsen market authorization was expected within six months and within that financial year. In Aug 2026, management said the product was still at least 3-4 quarters away from launch and that the launch roadmap was still being determined, representing a materially later and less certain commercialization timeline without an explanation for the change. Supply Chain Resolution Contradiction · 13 May 2026. During the February 2026 call, management explicitly stated that supply chain issues were resolved and that the company would see no more constraints starting from Q4. However, in the May 2026 call, they admitted that lingering supply constraints on legacy brands continued through Q4, reducing top-line growth by approximately 3.5% for the period. Bepirovirsen Market Authorization Delay · 13 May 2026. In February 2026, management estimated that the Hepatitis B treatment Bepirovirsen would receive market authorization within that financial year (FY2026). By the May 2026 call, management issued the same six-month timeline, effectively pushing the expected authorization date into the second half of the following financial year (FY2027). Every quote above is taken word for word from the company’s own earnings calls. ## How much does Glaxosmithkline Pharmaceuticals earn on its capital? Glaxosmithkline Pharmaceuticals Ltd earned a ROCE of 61% in FY26. That is up from a low of 22% in FY17. Its return on capital used (ROIC) is 25.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.1% net margin and 0.88× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 27.1% net margin × 0.88× asset turnover × 1.91× leverage (assets divided by equity) ≈ 45.5% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 37.9% − 12.0% = +25.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 37.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY23 at 529.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Glaxosmithkline Pharmaceuticals have too much debt? Glaxosmithkline Pharmaceuticals Ltd has total debt of ₹33.0 Cr against shareholder equity of ₹2,267 Cr as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Glaxosmithkline Pharmaceuticals shareholding pattern? Domestic institutions raised their stake in Glaxosmithkline Pharmaceuticals Ltd by 1.1 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 8.5% of the company. Foreign institutions moved +0.4 points over the same period, to 4.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +1.1 points over 8 quarters, to 8.5%; Foreign institutions: +0.4 points over 8 quarters, to 4.8%; Promoters: +0.0 points over 8 quarters, to 75.0%. Why the owners changed: domestic institutions drove it (+1.1 points). They raised their stake step by step. ## How far is Glaxosmithkline Pharmaceuticals from balance-sheet trouble? For Glaxosmithkline Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Glaxosmithkline Pharmaceuticals rank in its industry? 58.8 out of 100, rank 2 of 8 in Pharma - MNC bulk Drugs, with 96% of the evidence available. Glaxosmithkline Pharmaceuticals Ltd scores 58.8 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 2. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 18.1 + 19.1 + 6.4 + 15.2 = 58.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Glaxosmithkline Pharmaceuticals compared with? Glaxosmithkline Pharmaceuticals ranks 2 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 58.8 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. Glaxosmithkline Pharmaceuticals Ltd this page GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Glaxosmithkline Pharmaceuticals in size? Glaxosmithkline Pharmaceuticals is the 2nd largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Abbott India. Just below it: Pfizer, Astrazeneca Pharma India, Procter & Gamble Health, Sanofi Consumer Healthcare India and Sanofi India. ### Pharma - MNC bulk Drugs companies close in size

1. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ₹54,474 crore
2. Glaxosmithkline Pharmaceuticals Ltd ₹42,255 crore
3. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
4. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
5. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
6. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
7. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [Piramal Finance Ltd](https://www.sectoralpha.in/stocks/piramal-finance-ltd) ₹42,996 crore · Conglomerate Backed NBFC
2. [Sterlite Technologies Ltd](https://www.sectoralpha.in/stocks/sterlite-technologies-ltd) ₹42,397 crore · Cables - Telecom
3. Glaxosmithkline Pharmaceuticals Ltd ₹42,255 crore
4. [360 ONE WAM Ltd](https://www.sectoralpha.in/stocks/360-one-wam-ltd) ₹42,199 crore · Finance - Capital Markets - Wealth Management
5. [Authum Investment & Infrastructure Ltd](https://www.sectoralpha.in/stocks/authum-investment-infrastructure-ltd) ₹41,795 crore · Finance & Investments - Others

## What else do people ask about Glaxosmithkline Pharmaceuticals? ### What is Glaxosmithkline Pharmaceuticals's share price today? Glaxosmithkline Pharmaceuticals Ltd's share price is ₹2,575.10, −1.7% over the past year. The whole company is worth ₹43,629 Cr on the market. In the last 52 weeks it traded between ₹2,122 to ₹3,106; today it is 46% of the way up from the low, 0.6% below its 200-day average (as of 3 November 2026). ### What were Glaxosmithkline Pharmaceuticals's latest quarterly results? Glaxosmithkline Pharmaceuticals Ltd reported revenue of ₹938 Cr and net profit of ₹237 Cr for the Jun 2026 quarter. Revenue rose 16.5% and profit rose 15.6% compared with a year earlier. Earnings per share were ₹14.00. The operating margin was 31.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Glaxosmithkline Pharmaceuticals's market cap? Glaxosmithkline Pharmaceuticals Ltd's market capitalisation is ₹43,629 Cr at a share price of ₹2,575.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Glaxosmithkline Pharmaceuticals performing? Glaxosmithkline Pharmaceuticals Ltd's share price has been rising for 11 weeks. In its latest quarter, revenue rose 16.5% and profit rose 15.6% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Glaxosmithkline Pharmaceuticals's share price go up? This page does not forecast Glaxosmithkline Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹2,575.10, and it has been rising for 11 weeks. Its P/E of 41.4× is higher than 8% of its own last 11 years (as of 3 November 2026). ### Who owns Glaxosmithkline Pharmaceuticals? Promoters own 75.0% of Glaxosmithkline Pharmaceuticals Ltd, foreign institutions 4.8%, domestic institutions 8.5% and the public 11.8% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 1.1 percentage points over 8 quarters (as of 3 November 2026). ### Where is Glaxosmithkline Pharmaceuticals in its business cycle? Glaxosmithkline Pharmaceuticals Ltd's FY26 operating margin was 34.0%, against a 13-year range of 14.0% to 34.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 31.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Glaxosmithkline Pharmaceuticals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Glaxosmithkline Pharmaceuticals a stock worth studying right now? What the numbers show: Glaxosmithkline Pharmaceuticals Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 8% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Glaxosmithkline Pharmaceuticals share price forecast for 2026? What management itself guided: Established GenMed and vaccine businesses planned at 8-10% growth over the 4-5-year 2X horizon, with innovation driving the 13% growth ambition. What would change the story: Operating profit margin compressing below 28% across two consecutive quarters driven by volume deceleration in General Medicines combined with Shingrix quarterly dose run-rate dropping below 35,000 units. ## Lists

- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.